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ABSTRACT 
 
Objectives.  To obtain an objective, unbiased assessment of skin fibrosis in patients with 
systemic sclerosis (SSc) for use in clinical trials of SSc disease-modifying therapeutics.   
Methods.  Skin biopsies from the dorsal forearm of six patients with diffuse SSc and six healthy 
controls, and skin biopsies from the forearem of one patient with diffuse SSc before and 
following 1 year treatment with mycophenolate mofetil were analyzed by confocal laser 
scanning microscopy (CLSM) with specific antibodies against collagens type I and III or 
fibronectin. The integrated density of fluorescence (IDF) was calculated employing NIH-
ImageJ® software in at least four different fields per biopsy spanning the full dermal thickness.   
Results.  The intensities of types I and III collagen and fibronectin immunofluorescence were 
174%, 147%, and 139% higher in SSc skin than in normal skin, respectively.  All differences 
were statistically significant.  The sum of the IDF values obtained for the three proteins yielded a 
comprehensive fibrosis score.  The average fibrosis score for the six SSc samples was 28.3 x 106 
compared to 18.6 x 106 for the six normal skin samples (p < 0.0001).  Comparison of skin 
biopsies obtained from the same SSc patient before treatment and following 12 months 
mycophenolate mofetil treatment showed a reduction of 39% in total fibrosis score after 
treatment.    
Conclusion.  CLSM followed by quantitative image analysis provides an objective and unbiased 
assessment of skin fibrosis in SSc and could be a useful endpoint for clinical trials with disease 
modifying agents to monitor the response or progression of the disease.  
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Systemic sclerosis (SSc) is a heterogeneous autoimmune disorder characterized by 
excessive deposition of collagen and other extracellular matrix proteins in skin and multiple 
internal organs, microvascular dysfunction and humoral and cellular immune dysregulation (1).  
Uncontrolled production of collagens and other extracellular matrix (ECM) proteins by 
fibroblasts leads to excessive accumulation of connective tissue in various organs (1,2). The 
most apparent and almost universal clinical features of systemic sclerosis are related to the 
progressive thickening and fibrosis of the skin (3). The histopathologic findings in the skin 
include marked thickening of the dermis with massive accumulation of dense collagen causing 
epidermal atrophy, and replacement of sebaceous and sweat glands as well as hair follicles.  A 
prominent inflammatory infiltrate is often present, especially in early lesions (4,5).  Although the 
pathogenesis of SSc skin changes is not completely understood, the hallmark of skin 
involvement is the increased content of collagen and other extracellular matrix components such 
as fibronectin in the dermis (1,2).  The extent and rate of progression of tissue fibrosis is 
critically important in determining the clinical features and prognosis of SSc.  Skin thickening 
correlates with both survival6 and functional limitations in the disease (7), and extent or severity 
of skin involvement correlates with an overall assessment of clinical disease severity (8).   
The primary criterion used to classify patients as either SSc with diffuse or limited 
cutaneous involvement is the extent and severity of skin thickening (9). Skin involvement is the 
most widely used outcome measure in SSc interventional trials (10).  Currently, there is no 
widely accepted objective and quantitative measure of the amount of skin fibrosis in SSc for use 
in clinical trials to assess treatment success or disease progression and the gold standard outcome 
measure of skin involvement is the modified Rodnan skin score (mRSS), a semiquantitative 
assessment of cutaneous thickening performed by palpation and scoring of the degree of local 
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skin thickness in 17 body surface areas (11,12).  Studies have shown that higher skin scores 
correlate with worsening of internal organ involvement and higher morbidity and mortality in 
SSc (6-8)  and, therefore, it is generally accepted that the skin score can be used as a clinical 
surrogate of the overall disease process (10).  Although the mRSS is accessible, noninvasive and 
cost-effective, it is a subjective assessment with potential inter- and intra-observer variability, 
which has been calculated to be 25% and 12%, respectively (13).  This variability requires the 
recruitment of a large number of patients to appropriately power clinical studies, a difficult task 
given the low incidence of the disease.  Also, since the scale employed to grade the severity of 
skin thickening is limited to four integer values, it is difficult to quantify subtle skin changes.  
Furthermore, it is not possible to differentiate fibrotic skin thickening from that resulting from 
edema, inflammation, vascular bed engorgement, or skin tethering (14).       
To reduce subjectivity and increase reliability, investigators have employed device-
assisted measurements such as durometry and ultrasonography (14,15).  Although durometers 
provide a continuous scale and correlate with the mRSS, there is a similar inter-observer 
variability and a non-homogeneous sensitivity in uneven body regions (i.e. fingers, face) (15).  
As a result, none of the devices have been accepted as valid outcome measures for clinical 
studies.     
 Increased expression of the genes encoding interstitial collagens types I and III 
accompanied by marked elevations of the production of the corresponding proteins are the 
hallmark of SSc and are responsible for the pronounced abnormalities in skin and various 
internal organs.  Given the marked increase in the production and biosynthesis of interstitial 
collagens in SSc, numerous studies have investigated circulating or urinary levels of collagen 
molecules or collagen fragments as biomarkers that may reflect the activity of the ongoing 
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fibrotic process (16-19).  Although the measurements of metabolites derived from the 
biosynthesis and degradation of collagen are very likely a reflection of the fibrotic process, 
owing to the fact that most of the type I collagen in the body is present in bone, metabolites 
derived from this molecule would reflect, to a large extent, the remodeling and degradation of 
type I collagen in the skeletal system.   
Another protein that has been suggested as a potential biomarker to reflect the fibrotic 
process in SSc is the cartilage oligomeric matrix protein (COMP).  This large molecular weight 
pentameric protein was initially discovered as a product of articular cartilage chondrocytes and 
was considered to be specific for this tissue.  However, more recently it has been shown that 
COMP is also an important fibroblast and synoviocyte product (20) and therefore it has been 
suggested that serum COMP may reflect fibroblast biosynthesis of extracellular matrix 
components.  Indeed, some studies have measured serum levels of COMP and described 
significant correlations with the extent of skin involvement and with the severity of SSc (21).  
Increased expression of COMP was also demonstrated in skin samples from SSc patients as well 
as in fibroblasts cultured from these samples (22,23).   However, the possibility that COMP 
originated from articular cartilage may be a component of the serum COMP being detected or, 
more importantly, that it may represent a product of inflamed synovium needs to be further 
evaluated.  Thus, more extensive studies would be required to confirm the validity of 
measurements of collagen derived peptides and of COMP as markers of tissue fibrosis in SSc.   
Histopathological quantitation of fibroblastic cells expressing α-smooth muscle actin 
(myofibroblasts) has been suggested as another potential biomarker of SSc skin fibrosis (24).  In 
this study myofibroblast content in skin correlated with clinical measures of skin disease as well 
as with mRSS and showed a significant reduction following treatment with cyclophosphamide.  
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Thus, myofibroblasts may represent an early marker of the fibrotic process capable of being 
modulated by effective therapeutic interventions. 
The availability of an objective, reliable and reproducible quantitative method to assess 
the amount of skin fibrosis in SSc would be extremely valuable in determining the efficacy of 
disease-modifying interventions in clinical trials.  Reproducible observer-independent measures 
of skin disease would allow for smaller sample sizes and enhanced detection of effective 
therapies in clinical trials.  Here, we aimed to identify and quantify histopathologic markers of 
fibrotic activity in SSc skin biopsies that can be used as reliable biological endpoints for clinical 
trials of SSc disease modifying therapeutic agents.  For this purpose, we employed confocal laser 
scanning microscopy (CLSM) based quantitative analysis to assess the abundance of pertinent 
ECM proteins such as collagens types I and III, and fibronectin. 
 
PATIENTS AND METHODS 
 Patient selection.  Systemic sclerosis patients were recruited from the Scleroderma 
Center at Thomas Jefferson University.  All patients fulfilled the SSc classification criteria of the 
American College of Rheumatology (25), and had diffuse cutaneous involvement based on the 
criteria of LeRoy et al. (9).  All patients studied had SSc of recent onset (less than 18 months 
from first evidence of skin induration) and clinically evidenced rapid progression.  Skin biopsies 
were obtained within the first six months for four of the six patients studied. 
 Skin biopsies.  The Scleroderma Tissue Bank is a repository of tissue from patients with 
SSc which was established in 1987.  The skin samples maintained in the Tissue Bank are tissues 
remaining from biopsies obtained for diagnostic purposes from clinically affected skin.  For this 
study skin samples obtained from the dorsal forearm of six untreated patients with rapidly 
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progressive diffuse SSc of recent onset (less than 18 months from clinically detectable skin 
induration) were employed following an IRB approved protocol. Normal skin samples were 
obtained from patients undergoing unrelated surgical procedures.  To examine the effects of a 
therapeutic intervention, skin biopsies were obtained from one patient with diffuse SSc of recent 
onset (less than 10 months from clinically detectable skin induration) before treatment and 
following 12 months treatment with 2.0 g/day mycophenolate mofetil (MMF) orally.  The 
second biopsy was obtained from an area in close topographic proximity to the initial biopsy.  
The samples were fixed with 10% buffered formalin and embedded in paraffin.   
Skin Immunofluorescence.  After deparaffinizing the slides, tissue sections were 
incubated with a 1:100 dilution of specific primary rabbit polyclonal antibodies (Rockland 
Immunochemicals, Gilbertsville, PA) against collagens type I and type III, fibronectin or α-SMA 
for 1 h at room temperature in a moist, dark chamber.  Sections were washed twice with PBS.  
To minimize non-specific staining, slides were incubated with FAB’-sheep anti-rabbit Cy3 
antibody (Sigma, St. Louis, MO) for 1 h at room temperature.  The slides were then washed 
again in PBS and counterstained with DAPI-1500.  No antigen retrieval was performed since 
commonly used antigen retrieval procedures may cause variable extraction of tissue collagens or 
cell membrane alterations and cellular disruption resulting in increased background staining.     
Analysis of Fluorescence.  The entire skin section was scanned and four different low 
power magnification (20X) fields consecutively spanning the full thickness of the dermis were 
analyzed for each biopsy employing a Zeiss LSM 510 META confocal laser scanning 
microscope. The analyses were carried out in a blinded manner to disease/non-disease source of 
sample. A computer generated 2.5D image which plots the intensity of fluorescence of a specific 
microscopic field was employed for further analyses.  Each skin section was analyzed with 
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Image J® software, which calculated the sum of the intensity of each pixel in a given microscopic 
field as the Integrated Density of Fluorescence (IDF).  The IDF value is a measure of the overall 
amount of fluorescence intensity in a given microscopic field.  The averages of the four IDF 
values per specimen were calculated.  Statistical analysis of the average IDF values was 
performed using a 2-tailed unpaired t-test.  P values < 0.05 were considered significant.  
  
RESULTS 
Six patients with diffuse SSc (4 women, 2 men; median ± SD disease duration 8 ± 5 
months, age 39 ± 11 years) were recruited for the study. The disease duration was less than six 
months for 4 of the 6 patients.  The SSc biopsy samples were obtained from patients with early 
disease since this is the target population most commonly included in SSc disease modifying 
clinical trial studies.   Skin samples from 6 healthy subjects (4 women, 2 men; age 43 ± 17 
years) were used as normal controls.  The relevant clinical and serological characteristics of the 
patients are shown in Table 1.     
Figure 1 shows representative images of the analysis of fluorescence intensity in normal 
and SSc skin samples.  The left panels show representative images of the visual intensity of 
fluorescence, the center panels show the computer generated 2.5D analyses of the fluorescent 
images and the right panels show the Image J® software generated IDF values in arbitrary units.  
The Image J® generated IDF value for collagen I (Figure 1A) shows a high correlation with the 
visual intensity of fluorescence and, most importantly, it is an accurate assessment of total 
collagen I expression in the tissue section.  The average collagen I IDF in the normal skin was 
5.82 ± 0.87 x 106  vs. 10.13 ± 0.92 x 106 in the SSc skin (p = 0.0018).  Figures 1B and 1C show 
a similar analysis for collagen type III and fibronectin.  The average collagen III in normal skin 
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was 5.53 ± 0.69 x 106 vs. 8.10 ± 1.57 x 106 in the SSc skin (p = 0.0197).  The average fibronectin 
in the normal skin was 7.28 ± 0.51 x 106 vs. 10.10 ± 0.94 x 106 in the SSc skin (p = 0.0086).  The 
calculated amounts of type I collagen, type III collagen, and fibronectin were 174%, 147%, and 
139% higher in SSc skin than in normal skin, respectively.  All these differences were highly 
significant statistically.  Analysis of α-SMA was of little value as the calculated IDF included, in 
addition to myofibroblast or activated fibroblast signals, the intense signal originating from 
smooth muscle cells in small arterioles or surrounding hair follicles.   
The average IDF values of the 4 microscopic fields from the dermis of each of the 6 SSc 
skin samples and 6 normal skin samples stained for collagen I, collagen III, and fibronectin were 
analyzed by scatter plot (Figure 2A).  In order to obtain a comprehensive value of the amount of 
collagen I, collagen III, and fibronectin, we calculated and plotted the sum of the IDF values for 
all 3 ECM proteins as the total fibrosis score for each of the 6 SSc skin samples and 6 normal 
skin samples (Figure 2B).  The average total IDF score was 28.3 x 106 for the SSc skin samples 
compared to 18.6 x 106 for the normal skin samples.  Statistical analysis performed using a 2-
tailed unpaired t-test indicated that the differences in expression were all statistically significant 
(p < 0.0001).  
To examine whether the fibrosis score obtained as described above is static over time or 
sensitive to change we compared the fibrosis score in skin biopsies from one patient with diffuse 
SSc before and following 12 months of treatment with MMF.  The second biopsy was taken in 
close topographic proximity to the initial biopsy site and the ECM protein content and fibrosis 
score were obtained following staining for collagen I, collagen III, and fibronectin.  Two 
representative CLSM fields of the type I collagen staining in the dermis are shown in Figure 3A 
and the plotted IDF values of 7 separate microscopic fields spanning the dermis are shown in 
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Figure 3B. A profound decrease in fluorescent intensity is observed in the sample obtained 
following treatment compared to the initial biopsy obtained prior to treatment.  The IDF values 
obtained for all 7 microscopic fields were highly statistically significant , demonstrating the 
reliability of the method.  The sum of the average IDF values for collagen I (COL 1), collagen III 
(COL 3), and fibronectin (FBN) of the SSc skin biopsies taken before and following 1 year of 
treatment with MMF was analyzed as the total IDF fibrosis score.  The results showed that there 
was a 39% reduction in the total fibrosis score following 1 year of oral MMF treatment (Figure 
3C).   
 
DISCUSSION 
The goal of this study was to obtain an assessment of the extent of skin fibrosis in SSc 
patients that can be used as an objective and unbiased end point in clinical trials for SSc disease-
modifying therapeutics.  We determined the amounts of three ECM proteins known to be 
upregulated in SSc skin employing CLSM in skin biopsies from six patients with diffuse SSc and 
six healthy controls.  The amounts of type I collagen, type III collagen, and fibronectin were 
174%, 147%, and 139% higher in SSc skin than those in normal skin, respectively.  All 
differences were statistically significant.  In order to obtain an overall assessment of the amount 
of dermal fibrosis and of the total amount of collagen I, collagen III, and fibronectin in the tissue, 
the sum of the IDF values for all 3 ECM components was calculated as a total fibrosis score for 
each of the samples.  The total fibrosis score demonstrated a more pronounced difference 
between SSc and normal skin compared to the individual IDF values obtained separately for each 
ECM protein.  This observation may be explained by differences in stage of the disease which 
may result in increased abundance of a particular ECM protein at certain stages of disease 
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progression, and, therefore, a global or total fibrosis score may be more representative of the 
overall level of fibrosis in the tissue.        
Our results also suggest that the measurements obtained might be sensitive to change 
over time and are not static as they displayed a highly statistically significant reduction following 
12 months of oral treatment with MMF, a drug that has been recently suggested as a potentially 
effective antifibrotic agent (26,27) and has been used as a disease-modifying therapy for SSc-
associated lung disease (28-31) and diffuse cutaneous SSc of recent onset (32,33).  Our analyses 
showed a statistically significant 39% reduction in total fibrosis score following treatment which 
demonstrates that the assessment described here is capable of detecting a difference in skin 
fibrosis.  However, it was not possible to demonstrate a direct correlation between the fibrosis 
score  values obtained with this procedure and the mRSS or the assessment of skin induration 
obtained with a durometer in a previous study (14) (data not shown).  The failure to establish 
these correlations suggests that the parameters that are evaluated by the mRSS and durometer 
measurements are not the same as those being evaluated by the procedure described here.  It is 
likely that our method is a direct measurement of the accumulation of extracellular matrix 
macromolecules in the tissue and indeed reflects the level of tissue fibrosis, whereas the mRSS 
and durometer measurements may reflect in addition to tissue fibrosis other parameters such as, 
for example, tissue edema, severity and extent of the inflammatory process, tissue tethering, 
vascular engorgement, etc. 
The assessment described here is a substantial improvement compared to the qualitative 
histopathologic assessment performed routinely in skin biopsies.  Although the demonstration of 
increased collagen content in SSc skin biopsies is a rather obvious finding, the relevance and 
importance of the results reported here is twofold. First, the values were obtained with an 
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objective and unbiased (“investigator interpretation free”) method, and second, the assessment 
generated absolute numbers that can be used as an objective outcome measure of 
histopathological changes in SSc.  The values obtained by analyzing and quantifying the 
immunofluorescence intensity are sensitive enough to clearly distinguish between fibrotic and 
non-fibrotic skin.     
 Although clinical trials are a valuable means of evaluating the effectiveness of new 
treatments in SSc, the lack of an objective outcome measure with appropriate end-points for 
measuring treatment success in this disease makes interpretation and comparison of the findings 
difficult.  The development of an objective and reliable method of assessing the severity of skin 
fibrosis, therefore, would be invaluable in determining the efficacy of a given treatment in 
clinical trials, both by providing a method independent of the potential bias of study investigators 
and by allowing a reduction of the number of patients needed to achieve statistical power for the 
study.   
The modified Rodnan skin score (mRSS) is a clinical semi-quantitative assessment of 
skin thickness that is currently the only outcome measure widely used in clinical trials of disease 
modifying agents for SSc.  Although accessible and non-invasive, the mRSS has several 
limitations, ranging from the subjective assessment of skin palpation to the difficulty of scoring 
borderline skin changes and the confounding effects of the presence of edema, inflammation, or 
tethering and variability in skin adipose tissue.  Although hydroxyproline assays would yield a 
precise quantification of the amount of collagen in skin, there are drawbacks that limit its 
applicability, including the variability in wet weight of the samples caused by the difficulty of 
controlling loss of water content, the confounding and variable contribution of elastin 
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hydroxyproline to the overall results, and more importantly, the inability of hydroxyproline 
assays to differentiate between collagen types and to evaluate fibronectin content.   
 We do not foresee that CLSM followed by quantitative image analysis would be widely 
applicable in the clinical practice setting since skin biopsies are not typically necessary to 
establish the diagnosis.  However, this objective method may be used in clinical trials to compare 
the amount of tissue fibrosis before and following administration of a disease-modifying drug 
since two biopsies are often required as part of a clinical trial.  Thus, CLSM followed by 
quantitative image analysis may be a sensitive tool to assess the amount of skin fibrosis in SSc. 
Such analysis could be a useful endpoint for clinical trials to accurately monitor the response or 
progression of the disease.  However, further assessment of a larger number of patients will be 
required to validate this procedure. 
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Table 1.  Relevant clinical and serological characteristics of systemic sclerosis (SSc) patients. 
 Sex Age Duration* mRSS† 
Organ Involvement 
ANA 
Titer ANA Pattern Scl-70 ACA Lungs± Heart Kidneys 
Gastro- 
intestinal 
SSc-1 F 50 12 14 + + − + 
1:640        
1:160 
Speckled               
Homogeneous 
− − 
             
SSc-2 F 31 18 13 + − − + +  Not done + − 
             
SSc-3 M 57 4 23 + + − + 
1:610        
1:160 
Homogeneous          
Nucleolar 
+ − 
             
SSc-4 F 33 4 42 + +   − + 
1:1280     
1:80 
Homogeneous          
Nucleolar 
+ − 
             
SSc-5 M 35 6 24 − + − + 
Direct = 
266 
Not done  − − 
             
SSc-6 F 30 4 13 − − + − > 1:640 Nucleolar − − 
 
* Disease duration in months from earliest clinically detectable skin involvement. 
† mRSS at time of skin biopsy   
± Lung involvement classified as interstitial lung disease 
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LEGENDS FOR ILLUSTRATIONS 
Figure 1. Analysis of the fluorescence intensity for collagen I (A), collagen III (B) and fibronectin (C) in 
normal skin (N) and SSc skin (SSc).  The left panels show the immunofluorescence images, the center 
panels show the computer generated 2.5D image analysis plots of the corresponding microscopic fields, and 
the right panels show the IDF of the two microscopic fields calculated by Image J® software.     
 
Figure 2.  (A) The average IDF for collagen I (COL-1), collagen III (COL-3), and fibronectin (FBN) from 4 
different microscopic fields for each of the 6 SSc skin samples and 6 normal skin samples (N) analyzed by 
scatter plot. * = p< 0.05; ** = p <0.01; ***p < 0.001.  (B)  The sum of the IDF values for collagen I, 
collagen III, and fibronectin of each of the 6 SSc skin samples and 6 normal skin samples was analyzed as 
the total fibrosis score by scatter plot.  The red dotted line demonstrates that there is no overlap between the 
total fibrosis scores calculated for SSc skin and normal skin samples.  ***p < 0.001 
 
Figure 3.  (A) CLSM images of 2 representative fields of the dermis stained for collagen I (COL I) of a 
patient with diffuse SSc before treatment and after receiving oral treatment with  2.0 g/day MMF for 1 year.  
(B)  The IDF values of 7 microscopic fields stained for collagen I of the same SSc patient before treatment 
and after treatment were plotted.  ***p < 0.001.  (C)  The sum of the average IDF values for collagen I 
(COL I), collagen III (COL III), and fibronectin (FBN) of the SSc skin biopsy taken before and of the skin 
biopsy taken after treatment was analyzed as the total IDF score.  There is a reduction of 39% in fibrosis 
score after treatment with MMF for 1 year.   
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KEY MESSAGES 
• CLSM fibrosis score is an objective SSc skin fibrosis measurement independent from edema, 
inflammation, vascular engorgement, and other factors.  
• CLSM fibrosis score reflects clinically relevant therapeutic effects. 
 
 
 
